Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, April 2, 2014, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $278.57 to $71,423,275.14. Highlighted Stocks Traded by Insiders: DaVita HealthCare Partners (DVA) - FREE Research Report Mildenberger Laura who is Chief People Officer at DaVita HealthCare Partners sold 598 shares at $69.22 on April 2, 2014. Following this transaction, the Chief People Officer owned 5,438 shares meaning that the stake was reduced by 9.91% with the 598-share transaction. Staffieri Michael David who is COO, Kidney Care at DaVita HealthCare Partners sold 2,867 shares at $69.15 on April 2, 2014. Following this transaction, the COO, Kidney Care owned 2,633 shares meaning that the stake was reduced by 52.13% with the 2,867-share transaction. The shares most recently traded at $69.01, down $0.14, or 0.2% since the insider transaction. Historical insider transactions for DaVita HealthCare Partners go as follows:
4-Week # shares sold: 16,489
12-Week # shares sold: 26,489
24-Week # shares sold: 26,489
The average volume for DaVita HealthCare Partners has been 1.5 million shares per day over the past 30 days. DaVita HealthCare Partners has a market cap of $14.8 billion and is part of the health care sector and health services industry. Shares are up 9.01% year-to-date as of the close of trading on Wednesday. DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company has a P/E ratio of 24.0. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on DVA - FREETheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year, growth in earnings per share, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.